Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB have announced that their novel siRNA drug, RBD5044, has received approval to commence Phase II clinical trials in the European Union. This represents a significant step forward in the development of RNA interference therapies targeting lipid metabolism.
RBD5044: A Novel siRNA Drug Targeting ApoC3
RBD5044 is developed using the RIBO-GalSTARTM liver-targeting technology platform and is designed to decrease ApoC3 levels via siRNA-mediated gene silencing. The upcoming Phase II trial will be a randomized, double-blind, placebo-controlled, multi-center study aimed at evaluating the efficacy and safety of RBD5044 in patients with mixed hyperlipidemia.
Potential Impact on Cardiovascular Disease Risk
As a GalNAc-conjugated siRNA drug, RBD5044 effectively and precisely reduces plasma ApoC3 protein levels, a key component in triglyceride-rich atherogenic lipoproteins. Research indicates that plasma ApoC3 levels independently predict coronary events, while genetic studies link ApoC3 loss-of-function mutations and decreased plasma triglyceride levels to reduced cardiovascular disease risk. RBD5044 holds promise for lowering cardiovascular disease risks and may help mitigate recurrent acute pancreatitis in patients with severe hypertriglyceridemia by inhibiting ApoC3 and decreasing plasma triglyceride.
A Milestone in RNAi Therapeutics
RBD5044 is the second ApoC3-targeted siRNA drug to enter clinical development globally. Based on promising safety and efficacy data from its Phase I clinical trials, Ribo Life Science is optimistic about RBD5044’s potential to effectively treat mixed hyperlipidemia and hypertriglyceridemia.
About Suzhou Ribo Life Science
Suzhou Ribo Life Science focuses on developing RNA interference (RNAi) therapeutics and is a leading pioneer in China’s small nucleic acid technology and pharmaceutical industry. The company is committed to advancing the frontiers of international nucleic acid technology through iteration in chemical modifications and drug delivery techniques, establishing a comprehensive R&D platform for small nucleic acid drugs. Ribo Life Science has built a rich pipeline of products addressing cardiovascular metabolic diseases, liver diseases, kidney diseases, and rare disorders. Headquartered in Kunshan, Jiangsu, it also operates R&D centers in Beijing and Gothenburg, Sweden.
About Ribocure
Established in 2022, Ribocure serves as Ribo Life Science’s international R&D center in Gothenburg, Sweden. The center boasts a competitive pharmaceutical R&D and business development team, equipped with clinical trial facilities and laboratories, leading Ribo Life Science’s innovative siRNA drug development and commercialization efforts globally.-Fineline Info & Tech
Leave a Reply